The impact of pharmacist intervention on the intravenous-to-oral switch therapy of proton pump inhibitors in cardiovascular surgery

References

• Zhou X, Fang H, Xu J, et al. Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults - a meta-analysis of randomized controlled trials with trial sequential analysis. BMC Gastroenterol. 2019 Nov 21;19(1):193.
   PubMed Web of Science ®Google Scholar
• Larsen MD, Schou M, Kristiansen AS, et al. The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care. Eur J Clin Pharmacol. 2014 Jul;70(7):859–865.
   PubMed Web of Science ®Google Scholar
• Clarke K, Adler N, Agrawal D, et al. Indications for the use of proton pump inhibitors for stress ulcer prophylaxis and peptic ulcer bleeding in hospitalized patients. Am J Med. 2022 Mar;135(3):313–317.
   PubMed Web of Science ®Google Scholar
• MacLaren R, Kassel LE, Kiser TH, et al. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opin Drug Saf. 2015 Feb;14(2):269–280.
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123–1134.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706–715.
   PubMed Web of Science ®Google Scholar
• Xin C, Dong Z, Lin M, et al. The impact of pharmaceutical interventions on the rational use of proton pump inhibitors in a Chinese hospital. Patient Prefer Adherence. 2018;12:21–26.
   PubMed Web of Science ®Google Scholar
• Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015 Jul 6;14(3):7490–7501.
   PubMed Web of Science ®Google Scholar
• Buendgens L, Bruensing J, Matthes M, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014 Aug;29(4):696 e11–5.
   PubMed Web of Science ®Google Scholar
• Guidelines for clinical application of proton pump inhibitors, 2020. Available at: http://zs.kaipuyun.cn/s (Date of access 2020 Dec 10).
   Google Scholar
• Pharmaceutical Administration Committee of Chongqing Hospital Association. Expert consensus on proton pump inhibitor rule review. J ChinaPharm 2022; 33(8):897–910
   Google Scholar
• Expert Group on Prevention and Treatment of Stress Ulcers. Experts suggestions on stress ulcer prevention and treatment. Nat Med J China. 2018;98(42):3392–3395.
   Google Scholar
• File TM Jr., Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016 Oct 15;63(8):1007–1016.
   PubMed Web of Science ®Google Scholar
• Akhloufi H, Hulscher M, Melles DC, et al. Development of operationalized intravenous to oral antibiotic switch criteria. J Antimicrob Chemother. 2017 Feb;72(2):543–546.
   PubMed Web of Science ®Google Scholar
• Gasparetto J, Tuon FF, Dos Santos Oliveira D, et al. Intravenous-to-oral antibiotic switch therapy: a cross-sectional study in critical care units. BMC Infect Dis. 2019 Jul 22;19(1):650.
   PubMedGoogle Scholar
• Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: a practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents. 2020 Jan;55(1):105769.
   PubMed Web of Science ®Google Scholar
• Corny J, Perreau S, Thivilliers AP, et al. Strategies for reduction in the duration of intravenous drug use: interest of drug tracers as quality indicators to improve intravenous to oral switch. J Eval Clin Pract. 2017 Aug;23(4):848–852.
   PubMed Web of Science ®Google Scholar
• Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019 Jan 31;380(5):415–424.
   PubMed Web of Science ®Google Scholar
• Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52–62.
   PubMedGoogle Scholar
• Baker DE. Intravenous proton pump inhibitors. Rev Gastroenterol Disord. 2006 Winter;6(1):22–34.
   PubMedGoogle Scholar
• Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother. 2005 Oct;39(10):1667–1677.
   PubMed Web of Science ®Google Scholar
• Bundeff AW, Zaiken K. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013 May;19(4):325–333.
   PubMed Web of Science ®Google Scholar
• Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354–364.
   PubMed Web of Science ®Google Scholar
• Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association. Expert consensus on optimal application of proton pump inhibitors. Chin J Hosp Pharm. 2020;40(21):2195–2213.
   Google Scholar
• Zhou L, Ma J, Gao J, et al. Optimizing prophylactic antibiotic practice for cardiothoracic surgery by pharmacists’ effects. Medicine (Baltimore). 2016 Mar;95(9):e2753.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ma J, Bao J. Effect of pharmacist intervention on blood conservation therapy in total knee arthroplasty: a retrospective, observational study. Basic Clin Pharmacol Toxicol. 2019 Jun;124(6):681–690.
   PubMed Web of Science ®Google Scholar
• Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021 Jan-Feb;76(1):13–21.
   PubMed Web of Science ®Google Scholar
• Popovski Z, Mercuri M, Main C, et al. Multifaceted intervention to optimize antibiotic use for intra-abdominal infections. J Antimicrob Chemother. 2015 Apr;70(4):1226–1229.
   PubMed Web of Science ®Google Scholar
• Chen M, Cong L, He J, et al. Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement. Drug Discov Ther. 2020 Jul 15;14(3):145–148.
   PubMed Web of Science ®Google Scholar
• Lanas-Gimeno A, Hijos G, Lanas A. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019 Nov;18(11):1043–1053.
   PubMed Web of Science ®Google Scholar
• MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014 Apr;174(4):564–574.
   PubMed Web of Science ®Google Scholar
• Pappas M, Jolly S, Vijan S. Defining appropriate use of proton-pump inhibitors among medical inpatients. J Gen Intern Med. 2016 Apr;31(4):364–371.
   PubMed Web of Science ®Google Scholar
• De Kraker MEA, Abbas M, Huttner B, et al. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions. Clin Microbiol Infect. 2017 Nov;23(11):819–825.
   PubMed Web of Science ®Google Scholar
• Engel MF, Postma DF, Hulscher ME, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J. 2013 Jan;41(1):123–130.
   PubMed Web of Science ®Google Scholar